Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems
Source:Clin Interv Aging. 2008; 3(2):251-262.
Funding:HD02274/HD/NICHD NIH HHS/United States
HD036071/HD/NICHD NIH HHS/United States
K23 NS052487/NS/NINDS NIH HHS/United States
NS044299/NS/NINDS NIH HHS/United States
NS052487/NS/NINDS NIH HHS/United States
RL1AG032115/AG/NIA NIH HHS/United States
U10/CCU925123/CC/ODCDC CDC HHS/United States
UL1RR024922/RR/NCRR NIH HHS/United States
Description:Fragile X-associated tremor/ataxia syndrome (FXTAS) is a progressive neurological disorder that affects older adult carriers, predominantly males, of premutation alleles (55 to 200 CGG repeats) of the fragile X (FMR1) gene. Principal features of FXTAS are intention tremor, ataxia, parkinsonism, cognitive decline, and peripheral neuropathy; ancillary features include, autonomic dysfunction, and psychiatric symptoms of anxiety, depression, and disinhibition. Although controlled trials have not been carried out in individuals with FXTAS, there is a significant amount of anecdotal information regarding various treatment modalities. Moreover, there exists a great deal of evidence regarding the efficacy of various medications for treatment of other disorders (eg, Alzheimer disease) that have substantial phenotypic overlap with FXTAS. The current review summarizes what is currently known regarding the symptomatic treatment, or potential for treatment, of FXTAS.
You May Also Like: